pharmacie et médicaments – Développement substitution médicaments biologiques par médicaments biosimilaires

This written question concerns the substitution of biological medicines with biosimilar alternatives in France. It seeks clarification on the regulatory framework and potential impacts of such substitutions. The question addresses the implications for patients, healthcare providers, and the pharmaceutical industry, focusing on accessibility, cost-effectiveness, and therapeutic equivalence.